Join the Seizures group to help and get support from people like you.
Seizures News (Page 7)
Related terms: Complex Partial Seizure, Fits, Convulsion, Absence Seizure
Eisai Receives Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients
Tokyo, Japan – February 16, 2015 – Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval of an additional pediatric indication for Eisai’s antiepileptic drug (...
Upsher-Smith Receives FDA Approval for Qudexy XR (topiramate) Extended-Release Capsules
Maple Grove, MN – March 12, 2014 – Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced it received approval on March 11, 2014 from the U.S. Food and Drug Administration (FDA) for Qudexy XR...
FDA Approves Aptiom to Treat Seizures in Adults
November 8, 2013 – The U.S. Food and Drug Administration today approved Aptiom (eslicarbazepine acetate) as an add-on medication to treat seizures associated with epilepsy. Epilepsy is a brain...
FDA Medwatch Alert: Potiga (Ezogabine): Drug Safety Communication - Linked To Retinal Abnormalities And Blue Skin Discoloration
UPDATED 11/01/2013: FDA approved changes to the drug label, underscoring risks of abnormalities to the retina in the eye, potential vision loss, and skin discoloration, all of which may become ...
FDA Medwatch Alert: Valproate Anti-Seizure Products: Drug Safety Communication - Contraindicated for Pregnant Women for Prevention of Migraine Headaches
Including valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics ISSUE: FDA is advising health care...
FDA Medwatch Alert: Potiga (Ezogabine): Drug Safety Communication - Linked To Retinal Abnormalities And Blue Skin Discoloration
ISSUE: FDA is warning the public that the anti-seizure medication Potiga (Ezogabine) can cause blue skin discoloration and eye abnormalities characterized by pigment changes in the retina. FDA does...
FDA Approves Fycompa (perampanel) to Treat Partial Onset Seizures
October 23, 2012 – The U.S. Food and Drug Administration today approved Fycompa (perampanel) tablets to treat partial onset seizures in patients with epilepsy ages 12 years and older. Partial...
UCB Announces FDA Approval for Keppra in Infants and Children from One Month of Age with Partial Onset Seizures
ATLANTA--(BUSINESS WIRE)--Jan 25, 2012 - UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in...
FDA Approves Onfi for Seizures Associated with Lennox-Gastaut Syndrome
October 24, 2011 – On Oct. 21, the U.S. Food and Drug Administration approved Onfi tablets (clobazam) for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome...
Lundbeck Inc. Announces FDA Marketing Approval for Sabril for the Treatment of Two Difficult-to-Treat Epilepsies
DEERFIELD, Ill.--(BUSINESS WIRE)--Aug 21, 2009 - Lundbeck Inc. ("Lundbeck"), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug...
FDA Medwatch Alert: Antiepileptic Drugs
[UPDATE 05/05/2009] FDA notified healthcare professionals that it approved updated labeling for antiepileptic drugs used to treat epilepsy, psychiatric disorders, and other conditions (e.g., migraine...
Further information
Related condition support groups
Seizure Prevention, Seizure Prophylaxis, Epilepsy
Related drug support groups
gabapentin, clonazepam, Valium, diazepam, Topamax, pregabalin, lamotrigine, Depakote, topiramate, view more... Keppra, progesterone, Trileptal, oxcarbazepine, levetiracetam, Vimpat, phenobarbital